Keywords: rxs, abbott, mobic, soar, after, vioxx, withdrawal

US Rxs for Abbott's Mobic soar after Vioxx withdrawal, and its price rises 9%, says CU

Article | 13 June 2005

Print This

In the six months following September 2004's removal of Merck & Co's COX-2 inhibitor Vioxx (rofecoxib) from the US market (Marketletters ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in